ArticleLife (Basel, Switzerland)2026
AI-Assisted Preoperative Diagnosis of Wilms Tumor.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preoperative differentiation of Wilms tumor and neuroblastoma on pediatric abdominal computed tomography (CT) images may be challenging because of overlapping imaging features. We aimed to develop an artificial intelligence-assisted lesion-localization model for exploratory diagnostic support in this differential setting. In this single-center, retrospective, image-level study, a YOLO26s detector was trained on preoperative contrast-enhanced CT PNG images with histopathology-anchored labels. The dataset comprised 3553 images, including 2103 lesion-positive images and 1450 background-negative images, partitioned into training, validation, and test subsets. On the held-out test set, the model achieved a precision of 0.954, a recall of 0.951, an mAP@0.5 of 0.977, and an mAP@0.5:0.95 of 0.732. Class-specific mAP@0.5:0.95 values were 0.734 for neuroblastoma and 0.730 for Wilms tumor. At the image level, tumor-present versus background-negative discrimination yielded 99.5% sensitivity, 89.0% specificity, a 93.0% positive predictive value, a 99.2% negative predictive value, and 95.3% accuracy. YOLO26s showed strong within-dataset performance for lesion localization and differential support between Wilms tumor and neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.